Asundexian versus Apixaban in Patients with Atrial Fibrillation | NEJM
Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibit…